A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During, and Post-semaglutide Therapy

Launched by ACTIMED THERAPEUTICS LTD · Jul 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medicine called ACM-001.1 to see if it can help protect or improve muscle mass in adults who are obese and taking semaglutide, a drug commonly used to help with weight loss. While semaglutide helps people lose weight, it can sometimes also cause loss of muscle, which isn’t ideal. This study wants to find out if adding ACM-001.1 can reduce muscle loss during semaglutide treatment and help maintain or gain muscle after stopping semaglutide.

Adults with a body mass index (BMI) of 30 or higher who are eligible for semaglutide treatment can take part. However, people with certain health conditions like recent heart problems, uncontrolled high blood pressure, severe lung disease, or those who recently used similar weight-loss drugs or have type 2 diabetes with specific recent issues may not be eligible. Participants will receive the study drug along with semaglutide at first, and later continue with just the study drug after stopping semaglutide. This trial is currently recruiting adults of all genders, and those interested should discuss with their doctor to see if they qualify and to learn more about what involvement entails.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Eligible for treatment with semaglutide.
• • Have a BMI of ≥30.0 kg/m².
• Key Exclusion Criteria:
• Type 2 diabetes mellitus who in the preceding 90 days have either:
• • received a GLP-1RA (including semaglutide),
• • had a hypoglycaemic event,
• • lost \>5 kg weight,
• • had a HBA1C over 10.0%.
• • Any cardiovascular event within previous 6 months, uncontrolled hypertension, known congestive heart failure, or angina during the past year
• • Known severe chronic obstructive pulmonary disease (COPD)
• • Concomitant use of beta blockers and patients with contra indications to beta blockers